Buxton, M. B., Alexander, B. M., Berry, D. A., Cavenee, W. K., Colman, H., De Groot, J. F., … Cloughesy, T. F. (2020). GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).

Buxton, Meredith Becker, Brian Michael Alexander, Donald A. Berry, Webster K. Cavenee, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, et al. “GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.

Buxton MB, Alexander BM, Berry DA, Cavenee WK, Colman H, De Groot JF, et al. GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.

Buxton, Meredith Becker, et al. “GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 15, 2020.

Buxton MB, Alexander BM, Berry DA, Cavenee WK, Colman H, De Groot JF, Ellingson BM, Gordon GB, Khasraw M, Lassman AB, Li W, Lim M, Mellinghoff IK, Perry JR, Sulman EP, Tanner K, Weller M, Wen PY, Yung WKA, Cloughesy TF. GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. JOURNAL OF CLINICAL ONCOLOGY. 2020.